Blueberry Therapeutics

4 articles about Blueberry Therapeutics

• Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis

  11/13/2023

  Blueberry Therapeutics Limited announces that BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial in patients with onychomycosis, showing superiority over placebo with a high level of statistical significance.

• Blueberry Therapeutics Commence Phase I/II Clinical Trial Of Lead Product BB2603

  4/25/2017

• Blueberry Therapeutics Raises £3 Million Led By GM&C Life Sciences Fund

  5/4/2016

• Blueberry Therapeutics Release: Local Therapeutics Company Pioneering Nanotechnology To Bring Innovative Medicines To Market That Make A Real Difference To People’s Lives

  3/1/2016